机构：[1]State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.[2]Department of Pulmonary and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.[3]Department of Epidemiology, School of Public Health, Shanxi Medical University, Taiyuan 030001, China.[4]Sericulture and Apiculture Research Institute, Yunnan Academy of Agricultural Science, Mengzi 661100, China.[5]Department of Laboratory, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, China.[6]Department of Medicine, Tibet University, Lhasa 850001, China.
Nocardia is emerging as a serious and easily neglected pathogen in clinical practice with multidrug resistance that extends the treatment period for months or even years. This has led to the investigation of a vaccine approach to prevent Nocardia infections. However, studies on the protective proteins of Nocardia have not yet been carried out. In the present work, over 500 proteins in the supernatant of N. farcinica IFM10152 were identified by LC-MS/MS. In silico analysis of these proteins with a high content (score > 2000) predicted that NFA49590 was one of the conserved proteins in N. farcinica strains with potential antigenicity. After the rNFA49590 protein was cloned and expressed in E. coli (DE3) and purified using a Ni-NTA column, its good antigenicity was confirmed with sera from mice immunized with different Nocardia species by Western blot. Then we confirmed its ability to activate innate immunity by examining the phosphorylation status of ERK1/2, JNK, p38, and p65 and the cytokine levels of IL-6, TNF-α, and IL-10. Finally, we evaluated its immunoprotective effect in BALB/c mice, and we found that mice immunized with rNFA49590 protein exhibited high antibody titers, enhanced bacterial clearance ability, and generated robust protective effects from the N. farcinica challenge. These results offer strong support for the use of NFA49590 protein as a vaccine candidate and open the possibilities for the exploration of a large array of immunoprotective proteins.
基金：
the National Key R&D Program of China (grant numbers
2021YFC2301001) and the National Natural Science Foundation of China (grant number 82073624,
82102395)
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|3 区医学
小类|3 区微生物学
最新[2023]版：
大类|3 区医学
小类|3 区微生物学
第一作者：
第一作者机构：[1]State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Han Lichao,Ji Xingzhao,Yang Caixin,et al.Immunoprotective Analysis of the NFA49590 Protein from Nocardia farcinica IFM 10152 Demonstrates Its Potential as a Vaccine Candidate[J].Pathogens (Basel, Switzerland).2022,11(12):doi:10.3390/pathogens11121488.
APA：
Han Lichao,Ji Xingzhao,Yang Caixin,Zhao Shuo,Fan Shihong...&Li Zhenjun.(2022).Immunoprotective Analysis of the NFA49590 Protein from Nocardia farcinica IFM 10152 Demonstrates Its Potential as a Vaccine Candidate.Pathogens (Basel, Switzerland),11,(12)
MLA：
Han Lichao,et al."Immunoprotective Analysis of the NFA49590 Protein from Nocardia farcinica IFM 10152 Demonstrates Its Potential as a Vaccine Candidate".Pathogens (Basel, Switzerland) 11..12(2022)
